NCT04672434 2024-12-09Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor MalignanciesSymphogen A/SPhase 1 Completed48 enrolled
NCT03207347 2023-09-15A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)University of FloridaPhase 2 Completed37 enrolled 15 charts
NCT04430842 2023-01-18Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072SQuadriga Biosciences, Inc.Phase 1 Completed15 enrolled
NCT03071757 2022-04-28A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsAbbViePhase 1 Completed139 enrolled
NCT03000257 2022-04-14A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsAbbViePhase 1 Completed182 enrolled
NCT01773655 2020-07-01Clinical and Histopathologic Characteristics of BAP1 MutationsMemorial Sloan Kettering Cancer CenterCompleted196 enrolled